|
US4307016A
(en)
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
|
US4256746A
(en)
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
|
JPS55162791A
(en)
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
|
JPS5645483A
(en)
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
|
EP0028683A1
(en)
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotic C-15003 PHO and production thereof
|
|
JPS5645485A
(en)
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
|
WO1982001188A1
(en)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
4,5-deoxymaytansinoide compounds and process for preparing same
|
|
US4450254A
(en)
|
1980-11-03 |
1984-05-22 |
Standard Oil Company |
Impact improvement of high nitrile resins
|
|
US4313946A
(en)
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
|
US4315929A
(en)
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
|
JPS57192389A
(en)
|
1981-05-20 |
1982-11-26 |
Takeda Chem Ind Ltd |
Novel maytansinoid
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
IL106992A
(en)
|
1988-02-11 |
1994-06-24 |
Bristol Myers Squibb Co |
Acylhydrazone derivatives of anthracycline and methods for their preparation
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
ES2149768T3
(es)
|
1992-03-25 |
2000-11-16 |
Immunogen Inc |
Conjugados de agentes enlazantes de celulas derivados de cc-1065.
|
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
US5977316A
(en)
|
1995-01-17 |
1999-11-02 |
The Board Of Trustees Of The University Of Kentucky |
Monoclonal antibody 1A7 and related polypeptides
|
|
US7303749B1
(en)
|
1999-10-01 |
2007-12-04 |
Immunogen Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
AU775373B2
(en)
|
1999-10-01 |
2004-07-29 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
SG136804A1
(en)
|
2000-07-12 |
2007-11-29 |
Idec Pharma Corp |
Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
|
|
US6333410B1
(en)
|
2000-08-18 |
2001-12-25 |
Immunogen, Inc. |
Process for the preparation and purification of thiol-containing maytansinoids
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
US20030103971A1
(en)
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
|
EP1370292A1
(en)
|
2001-01-31 |
2003-12-17 |
Idec Pharmaceuticals Corporation |
Use of cd23 antagonists for the treatment of neoplastic disorders
|
|
JP4463475B2
(ja)
|
2001-01-31 |
2010-05-19 |
バイオジェン アイデック インコーポレイテッド |
腫瘍疾患の治療における免疫調節性抗体の使用
|
|
AU2002329540A1
(en)
|
2001-06-20 |
2003-01-02 |
Morphosys Ag |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
CN100339395C
(zh)
|
2001-11-08 |
2007-09-26 |
养生堂有限公司 |
戊型肝炎病毒单克隆抗体及其用途
|
|
EP2022799A2
(en)
|
2001-11-16 |
2009-02-11 |
Biogen Idec Inc. |
Polycistronic expression of antibodies
|
|
JP2006514627A
(ja)
|
2002-11-15 |
2006-05-11 |
イミューノメディクス、インコーポレイテッド |
治療薬の標的化送達のための多重特異的非共有結合複合体の使用
|
|
EP1572242B1
(en)
|
2002-12-13 |
2014-04-16 |
Immunomedics, Inc. |
Immunoconjugates with an intracellularly-cleavable linkage
|
|
US7534427B2
(en)
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
|
CA2525251C
(en)
|
2003-05-09 |
2015-10-27 |
Duke University |
Cd20-specific antibodies and methods employing same
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
|
US7241598B2
(en)
|
2004-06-29 |
2007-07-10 |
The Chinese University Of Hong Kong |
Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering
|
|
CA2572289A1
(en)
|
2004-06-30 |
2006-08-17 |
Centocor, Inc. |
Anti-mcp-1 antibodies, compositions, methods and uses
|
|
ES2408704T3
(es)
|
2005-01-05 |
2013-06-21 |
Biogen Idec Ma Inc. |
Moléculas de unión a Cripto
|
|
WO2006086586A2
(en)
|
2005-02-10 |
2006-08-17 |
Baylor Research Institute |
Anti-interferon alpha monoclonal antibodies and methods for use
|
|
US20060280738A1
(en)
|
2005-06-08 |
2006-12-14 |
Tedder Thomas F |
Anti-CD19 antibody therapy for transplantation
|
|
US8318906B2
(en)
|
2005-04-15 |
2012-11-27 |
The Regents Of The University Of California |
EMP2 antibodies and their therapeutic uses
|
|
WO2006117910A1
(ja)
|
2005-04-28 |
2006-11-09 |
Mochida Pharmaceutical Co., Ltd. |
抗血小板膜糖蛋白質ⅵモノクローナル抗体
|
|
ATE460672T1
(de)
|
2005-05-20 |
2010-03-15 |
Genentech Inc |
Vorbehandlung einer biologischen probe aus einem individuum mit autoimmunkrankheit
|
|
US20080279850A1
(en)
|
2005-07-25 |
2008-11-13 |
Trubion Pharmaceuticals, Inc. |
B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
|
|
HRP20140338T1
(hr)
|
2005-07-25 |
2014-06-20 |
Emergent Product Development Seattle, Llc |
Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
|
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
|
ES2567402T3
(es)
|
2006-05-30 |
2016-04-22 |
Genentech, Inc. |
Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos
|
|
WO2007146968A2
(en)
|
2006-06-12 |
2007-12-21 |
Trubion Pharmaceuticals, Inc. |
Single-chain multivalent binding proteins with effector function
|
|
MX2009001110A
(es)
|
2006-08-03 |
2009-05-11 |
Vaccinex Inc |
Anticuerpos monoclonales anti-il-6 y usos de los mismos.
|
|
CA2663536A1
(en)
|
2006-10-24 |
2008-05-02 |
Trubion Pharmaceuticals, Inc. |
Materials and methods for improved immunoglycoproteins
|
|
US7846434B2
(en)
|
2006-10-24 |
2010-12-07 |
Trubion Pharmaceuticals, Inc. |
Materials and methods for improved immunoglycoproteins
|
|
RS53008B2
(sr)
|
2007-04-03 |
2022-12-30 |
Amgen Res Munich Gmbh |
Interspecijski specifičan cd3-epsilon vezujući domen
|
|
JP2010532764A
(ja)
|
2007-07-06 |
2010-10-14 |
トゥルビオン・ファーマシューティカルズ・インコーポレーテッド |
Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
|
|
PE20140196A1
(es)
|
2007-08-09 |
2014-03-19 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
|
GB2454915B
(en)
|
2007-11-23 |
2012-02-15 |
Schlumberger Holdings |
Spooling apparatus for well intervention system
|
|
WO2009085575A2
(en)
|
2007-12-28 |
2009-07-09 |
Spring Bioscience Corporation |
Calibrator quality control cell device for immunohistochemistry assay and methods of use thereof
|
|
EP2365003A1
(en)
|
2008-04-11 |
2011-09-14 |
Emergent Product Development Seattle, LLC |
CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
|
US7740844B2
(en)
|
2008-04-29 |
2010-06-22 |
Taiwan Liposome Co. Ltd |
Anti-VEGF monoclonal antibody
|
|
KR20200058590A
(ko)
|
2008-04-30 |
2020-05-27 |
이뮤노젠 아이엔씨 |
가교제 및 그 용도
|
|
WO2010008726A1
(en)
|
2008-06-16 |
2010-01-21 |
Immunogen Inc. |
Novel synergistic effects
|
|
CN102159248B
(zh)
|
2008-07-15 |
2013-09-11 |
健泰科生物技术公司 |
蒽环类衍生物缀合物、它们的制备方法以及它们作为抗肿瘤化合物的用途
|
|
RU2526156C2
(ru)
|
2008-11-13 |
2014-08-20 |
ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи |
Cd37-иммунотерапевтическая комбинированная терапия и ее применения
|
|
EP2486023A4
(en)
|
2009-10-06 |
2014-05-07 |
Immunogen Inc |
EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
|
|
CN102958942A
(zh)
|
2009-12-29 |
2013-03-06 |
新兴产品开发西雅图有限公司 |
异二聚体结合蛋白及其应用
|
|
TW201129383A
(en)
|
2010-02-10 |
2011-09-01 |
Immunogen Inc |
CD20 antibodies and uses thereof
|
|
TW201129384A
(en)
|
2010-02-10 |
2011-09-01 |
Immunogen Inc |
CD20 antibodies and uses thereof
|
|
SG183542A1
(en)
|
2010-03-12 |
2012-10-30 |
Immunogen Inc |
Cd37-binding molecules and immunoconjugates thereof
|
|
KR20130108069A
(ko)
|
2010-04-15 |
2013-10-02 |
알퍼 바이오테크, 엘엘씨 |
Ｈｅｒ2 항원에 대한 모노클로날 항체 및 그를 위한 용도
|
|
RS58367B1
(sr)
|
2011-03-29 |
2019-03-29 |
Immunogen Inc |
Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
|
|
EP2694105A4
(en)
|
2011-04-01 |
2015-04-29 |
Immunogen Inc |
CD37 BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF
|
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
|
WO2013067581A1
(en)
*
|
2011-11-09 |
2013-05-16 |
Children's Cancer Institute Australia for Medical Research |
Cancer treatment
|
|
BR112014014258A2
(pt)
|
2011-12-13 |
2020-10-27 |
Nordic Nanovector As. |
molécula de anticorpo que se liga a cd37 humano; anticorpo; molécula de dna; vetor de expressão; célula hospedeira; método para produzir um anticorpo; composição farmacêutica; método de esgotamento de células b que expressam cd37 dentre uma população de células; radioimunoconjugado que se liga a cd37 humano; método de tratamento de uma malignidade de célula b; kit para a produção do radioimunoconjugado; e preparação injetável de anticorpo hh1 quimérico ou humanizado para uso no pré-tratamento de uma malignidade de célula b
|
|
HK1202156A1
(en)
|
2012-03-30 |
2015-09-18 |
Immunogen, Inc. |
Methods for increasing efficacy of cd37-based therapy
|
|
EP2849783A1
(en)
|
2012-05-16 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
Combination of cd37 antibodies with further agents
|
|
US20140120083A1
(en)
|
2012-11-01 |
2014-05-01 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using pi3 kinase isoform modulators
|
|
SI2900277T1
(sl)
|
2012-12-13 |
2022-05-31 |
Immunomedics, Inc. |
Odmerki imunokonjugatov protiteles in SN-38 za boljšo učinkovitost in zmanjšano toksičnost
|
|
WO2014143807A2
(en)
|
2013-03-15 |
2014-09-18 |
Stromatt Scott |
Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
|
|
US20160130659A1
(en)
|
2013-06-05 |
2016-05-12 |
Merck Sharp & Dohme Corp. |
Compositions and methods for treating cancer
|
|
BR112015030457A2
(pt)
|
2013-06-07 |
2017-08-22 |
Nordic Nanovector As |
Método para regular positivamente a expressão de antígeno
|
|
IL312865B2
(en)
|
2013-09-11 |
2025-06-01 |
Eagle Biologics Inc |
Liquid protein formulations containing viscosity-lowering agents
|
|
CN113995843A
(zh)
|
2013-11-07 |
2022-02-01 |
豪夫迈·罗氏有限公司 |
抗cd20抗体与btk抑制剂的组合疗法
|
|
WO2015116729A2
(en)
|
2014-01-28 |
2015-08-06 |
Emergent Product Development Seattle, Llc |
Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders
|
|
WO2015175533A2
(en)
|
2014-05-13 |
2015-11-19 |
Immunogen, Inc. |
Anti-cd37 immunoconjugate dosing regimens
|
|
SG10202108116SA
(en)
*
|
2015-06-08 |
2021-08-30 |
Debiopharm International S A |
Anti-cd37 immunoconjugate and anti-cd20 antibody combinations
|
|
US11104740B2
(en)
|
2015-08-28 |
2021-08-31 |
Debiopharm International, S.A. |
Antibodies and assays for detection of CD37
|
|
US11278629B2
(en)
|
2016-11-02 |
2022-03-22 |
Debiopharm International, S.A. |
Methods for improving anti-CD37 immunoconjugate therapy
|
|
US12144818B2
(en)
|
2018-05-30 |
2024-11-19 |
Debiopharm International, S.A. |
Method for treating cancer in a human patient by administering an anti-CD37 immunoconjugate using various dosing regimens
|